Philips Q2 Sales Up 9% On Chinese Healthcare Spending

Philips Q2 Sales Up 9% On Chinese Healthcare Spending
July 24, 2019

 

Shares of Koninklijke Philips N.V. (NYSE: PHG, PHGFF.PK) has gained roughly 7.50% or $3.50 in the past two days to trade at $47.29 after reporting higher-than-anticipated comparable sales in the second quarter. The Dutch health technology company generated a major portion of its revenue from the sales of its hospital equipment in the US and China markets. The company also reported higher profit and revenue in 2Q19, with narrower loss from discontinued operations.

Amsterdam headquartered Philips reported second-quarter sales of €4.67 billion, up 9% from €4.29 billion in the similar quarter last year. On a comparable basis, sales grew 6% with mid-single-digit growth in all business divisions.

Net income for the second-quarter was €246 million, up from €2 million last year. On a per-share basis, earnings were €0.27 in the recent quarter, compared with break-even in the year-ago period. The 2Q19 results include loss of €13 million from discontinued operations, compared with the prior year’s loss to €184 million.

Income from continuing operations rose to €260 million, or €0.28 per share, in Q2 2019, from €186 million, €0.20 per share, in the corresponding quarter last year.

Adjusted income from continuing operations was €0.43 per share, while adjusted EBITA margin was 11.8% of sales, compared with 11.2% in the similar period last year. Better performance of Diagnosis & Treatment division, in spite of unfavorable currency and tariff effect, led the margin growth.

Philips also revealed that comparable sales increased 6% in 2Q19. Analysts had anticipated 4.5% increase in comparable sales.

During the June quarter, sales in growth regions rose 9% on a comparable basis, led by double-digit growth in China. In developed regions, sales grew 5%. The company also reported 8% growth in comparable order, aided by the sustained demand for innovative products in Diagnosis & Treatment division, in spite of sluggishness in Connected Care division.

Commenting on the results, CEO Frans van Houten said, “We saw growth in all our segments in the second quarter and we expect that to continue. We had strong traction in emerging markets and that is set to continue. Also, we expect mature markets to come in stronger in the second half of the year.”

Going forward, the company anticipates to record 4% to 6% of comparable sales growth and adjusted EBITA margin increase of 100 basis point per year (on average) until 2020.

Van Houten said, “We continue to expect our performance momentum to further improve in the second half of the year, supported by sales growth and our productivity programs. We maintain our overall targets of 4-6 percent comparable sales growth and an Adjusted EBITA margin improvement of 100 basis points on average per year for the 2017-2020 period.”

The robust results and impressive revenue growth outlook is anticipated to keep the stock bullish in the short-term.

The historical price chart indicates that the stock is making new yearly highs. Furthermore, the MACD indicator is making new highs. As a result, we can expect the stock to move up in the short-term.

phg - techncial analysis - 24th July 2019

Disclaimer: Any financial trading analysis offered here is our opinion and is not intended as advice or direction for investors. We cannot guarantee the success of any trades made as a consequence of this article, and we encourage traders to incorporate a strong money management strategy to limit losses when they enter the markets. Please use this article as part of your own research before formulating strategies prior to trading.

Avatar

Andrew Wright

Prior to founding tradersasset.com in 2014, Andrew worked as a proprietary trader, then as a market maker. As a market maker, he traded options in over 100 stocks, he then began trading currency pairs in 2013. Andrew still actively trades both, and prides himself on educating and informing traders on the benefits of both Binary Options and Forex.


Related Articles

Novartis Raises FY18 Sales View, Acquires Endocyte

  The Swiss drugmaker, Novartis AG (NYSE: NVS), issued an upward revision of its full-year revenue outlook, citing growing sales

ThyssenKrupp at the Mercy of ECB and FED

  ThyssenKrupp AG (ETR:TKA) is one of Europe’s industrial giants. They employ over 150,000 employees in more than 80 countries

Caterpillar Beats 2Q17 Estimates, Raises FY17 View

  Last week, mining and earth moving equipment manufacturer Caterpillar Inc (NYSE: CAT) reported exceptional fiscal 2017 second-quarter results that